DEA Caps 2026 Drug Production: From Heroin to Sudafed Limits
Published Date: 11/28/2025
Notice
Summary
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2026. This affects drug makers and anyone involved in producing or using these substances. They’re asking for public comments by December 15, 2025, before finalizing the rules, which could impact production and supply next year.
Analyzed Economic Effects
7 provisions identified: 4 benefits, 2 costs, 1 mixed.
Proposed cuts to several Schedule II opioids
DEA proposes reduced 2026 aggregate production quotas for multiple Schedule II opioids — specifically codeine (for sale), morphine (for sale), fentanyl, hydrocodone (for sale), hydromorphone, oxycodone (for sale), and oxymorphone (for sale) — as reductions from their 2025 established APQ values; DEA observed an average 10.56 percent decrease in medical usage of those opioids in 2024 versus 2023.
Stimulant quotas: some kept, lisdexamfetamine raised
DEA observed a 6.74 percent increase in 2024 domestic use of Schedule II stimulants (amphetamine, methylphenidate, lisdexamfetamine) versus 2023. DEA proposes to set 2026 APQs for d-amphetamine (for sale), d,l-amphetamine, and methylphenidate at their 2025 adjusted APQ levels, and proposes to increase the lisdexamfetamine APQ from 2025 to meet an extrapolated 8.94 percent increase in domestic use and a 14.85 percent increase in export requirements for 2026; DEA also proposes a corresponding increase to d-amphetamine (for conversion) to support lisdexamfetamine manufacture.
AAN set for ephedrine, pseudoephedrine, phenylpropanolamine
DEA proposes the 2026 assessment of annual needs (AAN) for the List I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, and states the AAN includes imports of these chemicals (but excludes imports of controlled substances for use in industrial processes).
Higher remifentanil quota for 2026
DEA proposes a higher 2026 APQ for remifentanil than the 2025 established APQ to support increasing domestic medical use (used primarily intravenously during and after surgeries) and growing export requirements, based on rising domestic usage since 2020 and export increases from 2022–2024.
Noroxymorphone quota increased for product development
DEA proposes an increased 2026 APQ for noroxymorphone (for sale) from the 2025 established APQ to accommodate a manufacturer's request to manufacture reference standards, identify unknown impurities, and conduct product development manufacturing activities.
Higher Schedule I quotas for research substances
DEA proposes higher 2026 APQs than 2025 for certain Schedule I substances — including 3,4-methylenedioxy-N-methylcathinone, 5-methoxy-N,N-dimethyltryptamine, psilocybin, and psilocyn — to support increased research and clinical trials studying potential treatments for conditions such as PTSD and depression.
All other Schedule I/II quotas proposed at zero
DEA proposes that the APQ for all other Schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero for 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-21508 — Sunshine Act Meetings: Notice of Meeting Held With Less Than Seven Days Advance Notice
The FDIC held a public meeting with less than seven days' notice to discuss important banking rules and updates for 2026. This affects banks, especially community and big global ones, by adjusting rules on capital and advertising. No new costs were announced, but the timing means banks need to stay sharp and ready for changes soon.
Next: 2025-21510 — Privacy Act of 1974; System of Records
The Commodity Futures Trading Commission is updating how it shares certain personal records to better protect your info and prevent fraud. Starting December 29, 2025, they’ll share some data with the Treasury and can respond faster if there’s a data breach. If you’re involved with the CFTC, these changes help keep your info safer without costing you a dime.